Malmö 22 June 2026 **NEWSLETTER**

Progress in Apta-1 Manufacturing and New Insights from IOPC

Dear shareholders and stakeholders,

With summer just around the corner, this is a good opportunity to provide an update on our latest activities before the summer holiday period begins.

I recently returned from Athens, where our consulting CMC Director, Thomas Rupp, and I attended the International Oligonucleotides and Peptides Conference (IOPC). The conference served as a clear reminder that the oligonucleotide field continues to advance at an impressive pace. At the same time, it reinforced my conviction that our lead drug candidate, Apta-1, continues to distinguish itself from many other compounds under development through its unique mode of action and significant therapeutic potential.

Valuable insights and networking in Athens

IOPC provided valuable insights into new technologies that can improve product quality, scalability, and cost-effectiveness in oligonucleotide manufacturing.

The conference was also an excellent opportunity to meet potential new development partners and organizations active in the oligonucleotide field. I returned from Athens with fresh perspectives and continued confidence that the future of oligonucleotide-based therapeutics is very exciting.

An important advance in the manufacturing of Apta-1

Speaking of improved product quality and cost-effectiveness, I would like to highlight one of our most important recent achievements. Earlier this week, we announced that our partner Hongene Biotech had successfully produced a new test batch of Apta-1. By using a new conjugation method, we achieved very high product quality, with a purity level of approximately 99%.

Why is this so important? In drug development, the purity of the active pharmaceutical ingredient (API) is a fundamental quality metric. Put simply, high purity is a significant advantage. Although a lower purity level is not necessarily an insurmountable obstacle, achieving high purity can make subsequent manufacturing and development steps considerably less complex.

The result also represents a direct improvement in our production efficiency. Although the cost structure of smaller test batches differs from that of commercial-scale manufacturing, the improved yield and more efficient use of materials indicate that the new process has the potential to reduce the manufacturing cost of Apta-1 when produced at a larger scale.

It is also a major advantage that the batch was produced by an established international Contract Development and Manufacturing Organization (CDMO) such as Hongene Biotech. The company's extensive capabilities provide a strong foundation for scaling up the production of Apta-1 to larger volumes at a later stage, if and when required by a potential partner.

Paths to partnership

We expect these manufacturing results to strengthen our position, as the quality and maturity of manufacturing data are important factors when potential partners assess small biotechnology companies such as Aptahem.

Because, as you know, securing an agreement with such a partner or partners remains Aptahem's highest priority. As part of this work, we are now exploring the possibility of collaborating with academic partners and research companies, both in clinical studies and to expand non-clinical studies into new indications of interest.

Through such collaborations, we can enable highly qualified external researchers to test and evaluate our molecule in their own advanced systems, within clearly defined frameworks governing the use of the material and the handling of intellectual property rights. This could become an important mechanism for the independent validation of our science and help build confidence in Apta-1 ahead of potential discussions regarding a commercial partnership or licensing agreement.

Financial discipline and the road ahead

In closing, I would once again like to extend my sincere thanks to everyone who participated in our recent share issue. In today's challenging financial environment for biotechnology companies, these resources provide us with the operational flexibility required to continue our journey with a lean organization and strict financial discipline.

Our overarching goal remains unchanged and firmly in sight: to develop Apta-1 into a life-saving treatment for the millions of patients affected by sepsis and related acute medical conditions for which effective treatment options are still tragically lacking.

I wish you all a wonderful summer!

Follow us at aptahem.com or our social media, LinkedIn and Facebook.

Malmö 22 June 2026

Mikael Lindstam
CEO, Aptahem AB